Table 1.
Background of RA patients before denosumab treatment
| Clinical data | Before denosumab treatment |
|---|---|
| Number | 20 |
| Age (year) | 59.7 ± 11.3 |
| Female (%) | 100 |
| Disease duration (year) | 12.8 ± 11.1 |
| WBC (µl−1) | 5534 ± 2069 |
| Neutrophil (%) | 60.5 ± 11.0 |
| CRP (mg dl−1) | 0.21 ± 0.38 |
| ESR (mm h−1) | 27.4 ± 20.6 |
| MMP-3 (ng ml−1) | 69.1 ± 66.9 |
| SAA (µg ml−1) | 14.6 ± 27.5 |
| DAS28 ESR | 1.91 ± 1.27 |
| RF (mg dl−1) | 52.9 ± 49.1 |
| Osteocalcin (ng ml−1) | 0.41 ± 0.50 |
| TRAP-5b (ng ml−1) | 429 ± 157 |
| CTX (µg mmol−1) | 3.8 ± 1.12 |
| Treatments | TCZ (5), TCZ + FK506 (2) |
| ETN (2), ETN + MTX (1) | |
| MTX (6), MTX + PSL (4) |
Values are mean ± SD. CTX, collagen type 1 cross-linked C-telopeptide; ESR, erythrocyte sedimentation rate; ETN, etanercept; MMP-3, matrix metalloproteinase-3; PSL, prednisolone; RF, rheumatoid factor; SAA, serum amyloid A protein; TCZ, tocilizumab; WBC, white blood cell.